Dudnik, E.
225  Ergebnisse:
Personensuche X
?
1

P1.21-14 LIPI-based Score Predicting OS Benefit for the Add..:

Raphael, A. ; Kamm Feldman, A. ; Kian, W....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S240 , 2023
 
?
3

P2.16-05 Durvalumab+EP in Advanced Large-Cell Neuroendocrin..:

Dudnik, E. ; Ariel, L. ; Hod, K....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S376-S377 , 2023
 
?
4

133TiP Neoadjuvant osimertinib followed by sequential defin..:

Kian, W. ; Peled, N. ; Roisman, L.C....
Journal of Thoracic Oncology.  18 (2023)  4 - p. S115 , 2023
 
?
5

EP08.02-047 The Impact of CGP on the Decision-making Proces..:

Dudnik, E. ; Raphael, A. ; Holtzman, L....
Journal of Thoracic Oncology.  17 (2022)  9 - p. S419-S421 , 2022
 
?
6

EP08.02-122 Real-world Experience with Capmatinib in MET Ex..:

Illini, O. ; Fabikan, H. ; Swalduz, A....
Journal of Thoracic Oncology.  17 (2022)  9 - p. S460 , 2022
 
?
 
?
8

Clinical activity of brigatinib in ROS1-rearranged non-smal..:

the Israel Lung Cancer Group ; Dudnik, E. ; Agbarya, A....
Clinical and Translational Oncology.  22 (2020)  12 - p. 2303-2311 , 2020
 
?
 
?
10

6022 POSTER Plasma Levels of Heparanase as Marker of Tumour..:

Dudnik, E. ; Kuten, A.
European Journal of Cancer.  47 (2011)  - p. S398 , 2011
 
?
14

Investigation of changes in the order parameters near antip..:

Starostenkov, M. D. ; Dudnik, E. A.
Bulletin of the Russian Academy of Sciences: Physics.  71 (2007)  5 - p. 638-641 , 2007
 
1-15